Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110692 · ClinicalTrials.gov registry record · NA
Default Options to Reduce Unnecessary Daily Imaging During Palliative Radiation
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 1,188
- Enrollment target
NCT03110692: Completed NA study, sponsored by University of Pennsylvania.
NCT03110692 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 1,188 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03110692, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,188 participants
- Enrollment target
Study Summary
The goal of this study is to reduce preference sensitive, unnecessary daily imaging during radiation treatment in which a pre-planned quality improvement default option for radiation treatment prescriptions will be introduced throughout the network of Penn Radiation Oncology.
Primary Outcome
Radiology tests including x-rays and CT scans
Interventions
- BEHAVIORAL Default initiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,188 participants |
| Start Date | 2016-02-10 |
| Est. Completion | 2018-02-09 |
| Phase | NA |
What the finished NCT03110692 record still lists
NCT03110692 is an interventional study that assigns participants to a tested intervention. Its 1,188 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 1 intervention - of which Default initiation is the first listed.
NCT03110692 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03110692 about?
NCT03110692 is a clinical study titled "Default Options to Reduce Unnecessary Daily Imaging During Palliative Radiation". The goal of this study is to reduce preference sensitive, unnecessary daily imaging during radiation treatment in which a pre-planned quality improvement default option for radiation treatment prescriptions will be introduced throughout the network of Penn Radiation Oncology.
What is the current status of trial NCT03110692?
This trial is currently completed. It is a NA study. The enrollment target is 1,188 participants. The study started on 2016-02-10. Estimated completion is 2018-02-09.
What interventions are being tested in trial NCT03110692?
The interventions under investigation include: Default initiation (BEHAVIORAL).
Who is sponsoring clinical trial NCT03110692?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03110692's enrollment target sits among peer trials
1,188 89th of 2000 higher than 1,912 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
- NCT06290869 · 1,188 participants · Phase 3
Tobacco Education and Lung Health Study (TEAL)
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI